Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
Active, not recruiting · Phase 4 · NCT05722925
Conditions: Prostate Cancer
At a glance
- Research payments reported, 2025
- $20,666
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- OHSU Knight Cancer Institute (with Blue Earth Diagnostics, Oregon Health and Science University)
- Tested
- Fluciclovine PET/CT (drug)
- Dates
- Started 2023-10-04; completion 2026-12-01
- Results posted
- Not yet
The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.
From ClinicalTrials.gov, last updated 2026-06-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $20,666 in research payments for this study in 2025 (4 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.